FDA approves new treatment for patients with acute myeloid leukemia

November 21, 2018 – The U.S. Food and Drug Administration today approved glasdegib tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. “Intensive chemotherapy is usually used to control … (leggi tutto)